Brainomix E-Lung AI Imaging Technology Selected As Co-Primary Endpoint In Boehringer Ingelheim Phase 3 Clinical Trial In Pulmonary Fibrosis. <li /> The DROP-FPF trial is the first Phase 3 trial in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback